BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38241776)

  • 21. The effect of adenovirus-conjugated NDRG2 on p53-mediated apoptosis of hepatocarcinoma cells through attenuation of nucleotide excision repair capacity.
    Cao W; Zhang JL; Feng DY; Liu XW; Li Y; Wang LF; Yao LB; Zhang H; Zhang J
    Biomaterials; 2014 Jan; 35(3):993-1003. PubMed ID: 24383128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative Analysis of the Prognostic Significance of IDH,TERT, EGFR and MGMT Status in Patients with Adult Non-H3-Altered Grade 4 Gliomas: A Prospective Cohort Study.
    Alimohamadi M; Larijani A; Pour-Rashidi A; Farzin M; Ebrahimi H; Rahmani M; Hendi K; Yarandi KK; Aghajanian S; Shirani M
    World Neurosurg; 2024 Jan; 181():e628-e639. PubMed ID: 37914076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
    Mareike M; Franziska SB; Julia E; Daniel H; Michael S; Jörg F; Marion R
    J Neurooncol; 2021 Jul; 153(3):537-545. PubMed ID: 34185258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Epigenetic Regulator Jumonji Domain-Containing Protein 6 (JMJD6) Is Highly Expressed but Not Prognostic in IDH-Wildtype Glioblastoma Patients.
    Rosager AM; Dahlrot RH; Sørensen MD; Bangsø JA; Hansen S; Kristensen BW
    J Neuropathol Exp Neurol; 2022 Jan; 81(1):54-60. PubMed ID: 34875075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monocentric evaluation of Ki-67 labeling index in combination with a modified RPA score as a prognostic factor for survival in IDH-wildtype glioblastoma patients treated with radiochemotherapy.
    Dumke R; Dumke C; Eberle F; Nimsky C; Keber U; Engenhart-Cabillic R; Lautenschläger S
    Strahlenther Onkol; 2022 Oct; 198(10):892-906. PubMed ID: 35612598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of Casein kinase-2 induces p53-dependent cell cycle arrest and sensitizes glioblastoma cells to tumor necrosis factor (TNFα)-induced apoptosis through SIRT1 inhibition.
    Dixit D; Sharma V; Ghosh S; Mehta VS; Sen E
    Cell Death Dis; 2012 Feb; 3(2):e271. PubMed ID: 22318540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.
    Kawasoe T; Takeshima H; Yamashita S; Mizuguchi S; Fukushima T; Yokogami K; Yamasaki K
    J Neurosurg; 2015 Feb; 122(2):317-23. PubMed ID: 25415071
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular characteristics and clinical outcomes of elderly patients with IDH-wildtype glioblastomas: comparative study of older and younger cases in Kansai Network cohort.
    Fukai J; Arita H; Umehara T; Yoshioka E; Shofuda T; Kanematsu D; Kodama Y; Mano M; Kinoshita M; Okita Y; Nonaka M; Uda T; Tsuyuguchi N; Sakamoto D; Uematsu Y; Nakao N; Mori K; Kanemura Y
    Brain Tumor Pathol; 2020 Apr; 37(2):50-59. PubMed ID: 32361941
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
    Teske N; Karschnia P; Weller J; Siller S; Dorostkar MM; Herms J; von Baumgarten L; Tonn JC; Thon N
    J Neurooncol; 2022 Jan; 156(2):317-327. PubMed ID: 34902093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival.
    Chaurasia A; Park SH; Seo JW; Park CK
    J Korean Med Sci; 2016 Aug; 31(8):1208-14. PubMed ID: 27478330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1.
    Suwala AK; Stichel D; Schrimpf D; Maas SLN; Sill M; Dohmen H; Banan R; Reinhardt A; Sievers P; Hinz F; Blattner-Johnson M; Hartmann C; Schweizer L; Boldt HB; Kristensen BW; Schittenhelm J; Wood MD; Chotard G; Bjergvig R; Das A; Tabori U; Hasselblatt M; Korshunov A; Abdullaev Z; Quezado M; Aldape K; Harter PN; Snuderl M; Hench J; Frank S; Acker T; Brandner S; Winkler F; Wesseling P; Pfister SM; Reuss DE; Wick W; von Deimling A; Jones DTW; Sahm F
    Acta Neuropathol; 2021 Jul; 142(1):179-189. PubMed ID: 33876327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upregulation of P53 promotes nucleus pulposus cell apoptosis in intervertebral disc degeneration through upregulating NDRG2.
    Zhang K; Zhang Y; Zhang C; Zhu L
    Cell Biol Int; 2021 Sep; 45(9):1966-1975. PubMed ID: 34051015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activation of the NRF2 pathway and its impact on the prognosis of anaplastic glioma patients.
    Kanamori M; Higa T; Sonoda Y; Murakami S; Dodo M; Kitamura H; Taguchi K; Shibata T; Watanabe M; Suzuki H; Shibahara I; Saito R; Yamashita Y; Kumabe T; Yamamoto M; Motohashi H; Tominaga T
    Neuro Oncol; 2015 Apr; 17(4):555-65. PubMed ID: 25304134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma].
    Pan Y; Qi XL; Wang LM; Dong RF; Zhang M; Zheng DF; Chang Q; Zhong YF
    Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):292-8. PubMed ID: 24004584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic Value of PFKFB3 to PFKFB4 mRNA Ratio in Patients With Primary Glioblastoma (IDH-Wildtype).
    Kessler R; Fleischer M; Springsguth C; Bigl M; Warnke JP; Eschrich K
    J Neuropathol Exp Neurol; 2019 Sep; 78(9):865-870. PubMed ID: 31369092
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
    Juratli TA; Kirsch M; Geiger K; Klink B; Leipnitz E; Pinzer T; Soucek S; Schrock E; Schackert G; Krex D
    J Neurooncol; 2012 Dec; 110(3):325-33. PubMed ID: 23015095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions.
    Mata DA; Benhamida JK; Lin AL; Vanderbilt CM; Yang SR; Villafania LB; Ferguson DC; Jonsson P; Miller AM; Tabar V; Brennan CW; Moss NS; Sill M; Benayed R; Mellinghoff IK; Rosenblum MK; Arcila ME; Ladanyi M; Bale TA
    Acta Neuropathol Commun; 2020 Nov; 8(1):186. PubMed ID: 33168106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NDRG2 promotes adriamycin sensitivity through a Bad/p53 complex at the mitochondria in breast cancer.
    Wei Y; Yu S; Zhang Y; Zhang Y; Zhao H; Xiao Z; Yao L; Chen S; Zhang J
    Oncotarget; 2017 Apr; 8(17):29038-29047. PubMed ID: 28423695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma.
    Funakoshi Y; Hata N; Takigawa K; Arita H; Kuga D; Hatae R; Sangatsuda Y; Fujioka Y; Sako A; Umehara T; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iwaki T; Mizoguchi M
    Cancer Med; 2021 May; 10(10):3177-3187. PubMed ID: 33838014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rethinking extent of resection of contrast-enhancing and non-enhancing tumor: different survival impacts on adult-type diffuse gliomas in 2021 World Health Organization classification.
    Park YW; Kim S; Han K; Ahn SS; Moon JH; Kim EH; Kim J; Kang SG; Kim SH; Lee SK; Chang JH
    Eur Radiol; 2024 Feb; 34(2):1376-1387. PubMed ID: 37608093
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.